Transcriptome analysis

OTHER4 trials

Sponsors

University Hospital, Rouen, Thomas Mueller, OmicsWay Corp.

Conditions

Antibody-mediated RejectionCancerDermatomyositisHER2-positive Breast CancerPolymyositis

Unknown Phase

myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies

CompletedNCT00213629

University Hospital, RouenDermatomyositis, Polymyositis

Start: 2004-11-30End: 2010-07-31Updated: 2012-02-16

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

Thomas MuellerAntibody-mediated Rejection

Start: 2018-02-15End: 2018-04-30Target: 50Updated: 2018-02-12

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

OmicsWay Corp.HER2-positive Breast Cancer

Start: 2017-10-01End: 2022-05-01Target: 40Updated: 2021-09-14

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

OmicsWay Corp.Cancer

Start: 2017-10-17End: 2022-11-01Target: 200Updated: 2021-09-14

Related Papers

Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney Transplants

Frontiers in Medicine2022-04-29

Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels

Biochemistry (Moscow)2020-06-2424 citations

Clinical use of RNA sequencing and oncobox analytics to predict personalized targeted therapeutic efficacy.

Journal of Clinical Oncology2020-05-2011 citations

Oncobox, gene expression-based second opinion system for predicting response to treatment in advanced solid tumors.

Journal of Clinical Oncology2019-05-2021 citations